Inve US ▾
APAPYX

Apyx Medical (APYX) Q2 FY26 earnings call: guidance and Q&A

Earnings call· Jun 2026 (Q2 FY26)· Health Care· Aug 6, 2026

Source: earnings call transcript

Executive summary

Apyx Medical Q2 FY26 — AYON Platform Drives Strong Growth and Expanded Capabilities

Apyx Medical delivered robust second-quarter results, primarily fueled by the strong performance of its Surgical Aesthetics segment and the growing adoption of the AYON platform. The company expanded AYON's capabilities with FDA clearance for power liposuction, which is expected to further enhance its market position. Management reaffirmed full-year revenue and margin guidance, expressing confidence in continued growth and liquidity into 2028, despite ongoing OEM segment decline and increased cash usage in operations.

Highlights

5

  • Total revenue increased 22% year-over-year to $13.9 million.

  • Surgical Aesthetics segment revenue grew 28% to $12.4 million, driven by AYON sales and Renuvion handpieces.

  • Gross profit margin expanded to 63.9% from 62.3% in the prior year period.

  • Adjusted EBITDA loss improved significantly to $0.7 million from $2.0 million in Q2 FY25.

  • FDA 510(k) clearance for power liposuction on the AYON platform, with positive initial commercial shipments.

Concerns

3

  • OEM segment revenue decreased 12% to $1.5 million due to lower sales volume to existing customers.

  • Net cash used in operating activities increased to $3.5 million compared to $1.2 million in the prior year.

  • Tariffs partially offset gross margin expansion, impacting the second half of 2025 and continuing into 2026.

Guidance & targets

CategoryTargetConfidence
Full-year Total Revenue
$59.0 million to $60.0 million
high materiality
High
Full-year Surgical Aesthetics Segment Revenue
$54.0 million to $55.0 million
high materiality
High
Full-year OEM Segment Revenue
$5.0 million
medium materiality
High
Full-year Gross Margins
62% to 63%
high materiality
High
Full-year Total Operating Expenses
not to exceed $45.0 million
medium materiality
High

Segment performance

SegmentRevenueYoYQoQMargin
Surgical Aesthetics
Revenue increased by $2.7 million compared to $9.7 million in the prior year period. Growth was driven by sales of the AYON Body Contouring System, increased Renuvion generator sales internationally, and increased volume of single-use handpieces domestically.
$12.4 million28%——
OEM
Revenue decreased by approximately $0.2 million compared to $1.7 million in the prior year period. The decrease was due to lower sales volume to existing customers. The company expects this segment's revenue to decrease for the full year and over time due to an increased focus on surgical aesthetics.
$1.5 million-12%——
Domestic Revenue
Year-over-year growth.
$9.4 million21%——
International Revenue
Year-over-year growth.
$4.5 million24%——

Product announcements

ProductTypeDetails
Power Liposuction for AYON Body Contouring Systemexpansion

Risks & headwinds

Tariffs Began affecting in H2 2025, continuing into 2026.

Partially offset gross margin expansion.

Mitigation:Company is seeking tariff refunds, but these are not included in current guidance.

OEM segment decline Ongoing trend, expected to continue over time.

Decreased 12% YoY to $1.5 million in Q2 FY26. Expected to decrease for the full year (to $5.0 million from $7.5 million in FY25).

Mitigation:Increased focus on Surgical Aesthetics segment.

Increased cash usage in operating activities Q2 FY26.

$3.5 million used in Q2 FY26 vs $1.2 million in Q2 FY25.

Mitigation:Management focused on growing sales, managing expenses, and getting to cash flow positive as quickly as possible; projects sufficient liquidity into 2028.

What to watch in Q3 FY26

Power Liposuction Commercial Launch

Q3 FY26
Current Initial commercial shipments in June 2026
Target Successful full commercial launch and ramp-up in Q3 FY26

Why it matters

Power Lipo is expected to significantly enhance the AYON platform's competitiveness and drive recurring revenue, impacting future growth and margins.

We look forward to the full commercial launch of power liposuction in the third quarter as the next step in building our AYON platform.

Find out whether APYX delivers this. Inve re-checks your case every morning.

Q&A highlights

Are new AYON users typically existing Renuvion users or new customers? Are they primarily plastic surgeons?

Yes, Apyx is acquiring new customers who have never used Renuvion before through AYON. The primary users are plastic or cosmetic surgeons focused on body contouring and GLP-1 patients.

“Yes. So the answer to the first part of the question is yes. We are getting people that have never used Renuvion before that are buying the AYON platform.”

asked by Dave Turkaly · answered by Charles Goodwin

2 min read 6 chapters

Detailed narrative

AYON Platform Traction and Expansion

The AYON Body Contouring System, following its full commercial launch in September 2025, continues to gain traction in the U.S. market. Surgeons are increasingly recognizing its value as an integrated all-in-one platform combining core technologies. The company received expanded 510(k) clearance from the FDA to add power liposuction to AYON, which commenced initial commercial shipments in June 2026 after positive limited commercial launch feedback. This enhancement allows for more efficient fat removal and body sculpting.

GLP-1 Opportunity

The rapid adoption of GLP-1 medications is creating a significant long-term opportunity for Apyx. As patients achieve substantial weight loss, many are left with loose or lax skin, which AYON's comprehensive body contouring capabilities, combining fat removal, Renuvion tissue contraction, and electrosurgical features, are well-positioned to address. This trend is expected to drive future demand for the company's offerings.

Clinical Evidence and Awareness

Apyx continues to build its clinical foundation with new peer-reviewed publications. A retrospective study showed Renuvion combined with liposuction led to higher patient satisfaction and reduced need for more invasive procedures compared to liposuction alone, with comparable complication rates. A prospective study also demonstrated visible improvements in cellulite and skin laxity with Avéli and Renuvion, showing progressive tissue remodeling. The company also showcased its platform at Miami Swim Week, highlighting aesthetic outcomes.

Executive Leadership Appointment

Stavros Vizirgianakis has been appointed Executive Chairman of the Board of Directors. This formalizes his already significant involvement in shaping strategic priorities, supporting financing initiatives, and strengthening operational focus, leveraging his decades of leadership experience and industry network to drive long-term shareholder value.

OEM Segment Strategy

The OEM segment experienced a 12% decrease in sales, reflecting a continued trend. The company expects OEM revenue to decrease for the full year and over time, as it maintains an increased focus on the higher-growth Surgical Aesthetics segment.

Liquidity and Cash Flow

The company reported $27.6 million in cash and cash equivalents as of June 30, 2026. Despite an increase in net cash used in operating activities to $3.5 million, management projects sufficient liquidity into 2028, based on AYON uptake, working capital management, and strict cost controls, with a focus on achieving cash flow positive status.

Summary of the company's earnings call; see how call summaries are prepared. Not investment advice.